Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
BIO

BIO - Bio-Rad Laboratories Inc Stock Price, Fair Value and News

296.80USD-3.47 (-1.16%)Market Closed

Market Summary

BIO
USD296.80-3.47
Market Closed
-1.16%

BIO Stock Price

View Fullscreen

BIO RSI Chart

BIO Valuation

Market Cap

8.5B

Price/Earnings (Trailing)

-26.25

Price/Sales (Trailing)

3.25

EV/EBITDA

-23.4

Price/Free Cashflow

45.63

BIO Price/Sales (Trailing)

BIO Profitability

EBT Margin

-17.04%

Return on Equity

-3.56%

Return on Assets

-2.56%

Free Cashflow Yield

2.19%

BIO Fundamentals

BIO Revenue

Revenue (TTM)

2.6B

Rev. Growth (Yr)

-9.75%

Rev. Growth (Qtr)

-10.33%

BIO Earnings

Earnings (TTM)

-322.4M

Earnings Growth (Yr)

456.71%

Earnings Growth (Qtr)

9.78%

Breaking Down BIO Revenue

Last 7 days

-2.4%

Last 30 days

2.7%

Last 90 days

6.1%

Trailing 12 Months

-25.5%

How does BIO drawdown profile look like?

BIO Financial Health

Current Ratio

6.57

Debt/Equity

0.13

Debt/Cashflow

0.29

BIO Investor Care

Buy Backs (1Y)

3.64%

Diluted EPS (TTM)

-10.36

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20242.6B000
20232.8B2.8B2.7B2.7B
20222.9B2.9B2.8B2.8B
20212.7B2.9B3.0B2.9B
20202.3B2.3B2.4B2.5B
20192.3B2.3B2.3B2.3B
20182.2B2.3B2.3B2.3B
20172.1B2.1B2.1B2.2B
20162.0B2.0B2.1B2.1B
20152.1B2.1B2.0B2.0B
20142.1B2.2B2.2B2.2B
20132.1B2.1B2.1B2.1B
20122.1B2.1B2.0B2.1B
20112.0B2.0B2.1B2.1B
20101.8B1.9B1.9B1.9B
200901.8B1.8B1.8B
20080001.8B
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022


Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Which funds bought or sold BIO recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 19, 2024
Continuum Advisory, LLC
unchanged
-
-67.00
4,370
-%
Jul 19, 2024
RAYMOND JAMES & ASSOCIATES
reduced
-2.23
-1,107,690
3,751,430
-%
Jul 19, 2024
Sumitomo Mitsui Trust Holdings, Inc.
reduced
-8.25
-4,817,610
12,669,600
0.01%
Jul 19, 2024
Venturi Wealth Management, LLC
reduced
-67.5
-10,284
3,552
-%
Jul 19, 2024
VAUGHAN NELSON INVESTMENT MANAGEMENT, L.P.
added
10.98
-258,000
1,821,000
0.02%
Jul 19, 2024
NISA INVESTMENT ADVISORS, LLC
reduced
-15.64
-75,296
150,211
-%
Jul 19, 2024
First Horizon Advisors, Inc.
reduced
-32.25
-64,334
74,013
-%
Jul 19, 2024
Oakworth Capital, Inc.
unchanged
-
-1,091
4,097
-%
Jul 18, 2024
Blue Trust, Inc.
added
19.97
49,460
297,103
-%
Jul 18, 2024
Assenagon Asset Management S.A.
added
36.26
1,047,050
14,838,600
0.03%

1–10 of 50

Are Funds Buying or Selling BIO?

Are funds buying BIO calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own BIO
No. of Funds

Unveiling Bio-Rad Laboratories Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Mar 11, 2024
vanguard group inc
10.36%
2,427,137
SC 13G/A
Feb 13, 2024
vanguard group inc
9.93%
2,389,889
SC 13G/A
Jan 29, 2024
blackrock inc.
6.1%
1,466,226
SC 13G/A
Feb 09, 2023
vanguard group inc
9.66%
2,391,436
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 01, 2023
blackrock inc.
6.4%
1,582,313
SC 13G/A
Apr 11, 2022
schwartz alice n
89.7%
4,555,452
SC 13D/A
Feb 09, 2022
fmr llc
-
0
SC 13G/A
Feb 09, 2022
vanguard group inc
9.21%
2,287,465
SC 13G/A
Feb 01, 2022
blackrock inc.
7.1%
1,768,081
SC 13G/A

Recent SEC filings of Bio-Rad Laboratories Inc

View All Filings
Date Filed Form Type Document
Jun 17, 2024
3
Insider Trading
Jun 14, 2024
4
Insider Trading
Jun 13, 2024
144
Notice of Insider Sale Intent
May 09, 2024
SD
SD
May 08, 2024
S-8
Employee Benefits Plan
May 08, 2024
3
Insider Trading
May 08, 2024
10-Q
Quarterly Report
May 07, 2024
8-K
Current Report
May 01, 2024
4
Insider Trading
Apr 30, 2024
4
Insider Trading

Peers (Alternatives to Bio-Rad Laboratories Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
177.6B
40.3B
-1.87% -8.75%
31.54
4.4
-2.84% -3.00%
66.7B
19.7B
-1.27% -12.39%
50.03
3.38
4.82% -17.56%
18.9B
3.9B
3.77% -24.06%
40.93
4.83
5.72% 46.72%
18.0B
14.9B
4.77% -28.30%
6.8
1.21
2.98% 207.68%
MID-CAP
9.7B
3.5B
-0.49% 22.32%
30.92
2.73
6.16% 35.06%
9.0B
12.4B
3.05% -11.95%
23.22
0.73
-0.93% -18.83%
8.5B
2.6B
2.70% -25.47%
-26.25
3.25
-6.25% -68.58%
5.5B
3.9B
2.69% -35.08%
-57.29
1.39
0.23% 90.80%
3.5B
387.1M
0.41% 33.97%
-217.07
8.93
30.82% 65.57%
2.2B
6.6B
-1.26% -22.56%
11.83
0.33
1.50% -10.09%
SMALL-CAP
1.4B
3.2B
-5.25% -24.25%
-2.04
0.44
7.94% -1695.32%
408.8M
169.3M
6.32% 8.33%
-5.32
2.42
7.49% -244.90%
287.6M
324.0M
27.08% -17.85%
-1.5
0.89
-3.19% -337.41%
46.8M
50.5M
-0.74% -76.96%
-2.05
0.93
14.25% -10.06%
5.7M
3.5M
-39.71% -89.21%
-0.47
1.62
-0.62% -1.48%

Bio-Rad Laboratories Inc News

Latest updates
American Banking and Market News5 hours ago
Yahoo Singapore News44 hours ago
MarketBeat19 Jul 202403:01 pm

Bio-Rad Laboratories Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-10.3%611681632681677730681691700733747716727790647537572625561573554
Gross Profit-11.0%326366336363362397373395403400437401401460367293317330307308312
  S&GA Expenses3.7%215207201208226212211208197222216213226218198189194214202201208
  R&D Expenses3.9%66.0064.0044.0065.0075.0066.0067.0064.0060.0059.0064.0063.0074.0057.0060.0052.0049.0057.0048.0050.0048.00
EBITDA Margin49.5%-0.15*-0.30*0.00*-0.12*-0.02*-1.61*-2.73*-0.85*-0.02*1.91*2.93*1.87*2.03*2.00*1.97*1.17*0.94*1.05*0.30*0.60*0.41*
Interest Expenses-0.7%12.0012.0012.0012.0012.0012.0012.0011.004.000.000.000.000.005.006.006.006.006.006.006.006.00
Income Taxes36.2%10779.0031.00-33816.00264-44.51-295-1,000-4611,094243320242370280213146-76.40171262
Earnings Before Taxes14.6%491428137-1,50085.001,091-207-1,220-4,368-2,0275,0221,1571,2971,0891,6841,246899699-3357701,127
EBT Margin46.5%-0.17*-0.32*-0.07*-0.19*-0.09*-1.68*-2.79*-0.90*-0.07*1.86*2.87*1.82*1.97*1.93*1.90*1.09*0.87*0.98*0.23*0.53*0.34*
Net Income9.8%384350106-1,16269.00828-162-925-3,367-1,5723,9309179808391,315966686554-258599865
Net Income Margin48.1%-0.12*-0.24*-0.06*-0.15*-0.07*-1.29*-2.15*-0.67*-0.03*1.46*2.24*1.41*1.52*1.50*1.48*0.85*0.68*0.76*0.16*0.40*0.25*
Free Cashflow-23.7%30.0039.0054.0063.0062.0045.00-16.5836.0017.0011519613194.0024611674.0041.0013869.0013319.00
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets2.5%12,61012,29911,89611,97813,66713,50212,05812,68214,37417,79919,95315,11813,93312,97312,02110,0978,6848,0097,1777,6476,863
  Current Assets0.4%3,0613,0483,1473,1393,2773,1583,1403,2503,3031,9902,4662,2892,1752,1402,3242,1332,0832,1802,0482,0882,032
    Cash Equivalents7.3%433404458390464435518597802471860733673667840608604663561581456
  Inventory0.4%783781776777753719686657605572589599605622640628557554588590590
  Net PPE-100.0%-529---499---512---491--486499496499503
  Goodwill-0.2%413414407412408407400347346347292292292292292292264264264235231
Liabilities0.0%3,5593,5583,4803,5313,9043,8863,6053,7604,1914,1144,6213,5233,3243,0933,1962,7442,3912,2542,0462,1601,999
  Current Liabilities-10.8%466523558582590569571614648681650587610632987927869905434446444
  Long Term Debt0.0%1,1991,1991,1991,1981,1981,1981,1971,1971,19711.0011.0011.0011.0012.0012.0012.0012.0014.00438438438
    LT Debt, Non Current0.0%1,1991,1991,1991,1981,1981,1981,1971,1971,19711.0011.0011.0011.0012.0012.0012.0012.0014.00438438438
Shareholder's Equity3.5%9,0518,7418,4168,4479,7649,6158,4778,94510,20313,68515,33211,59510,6099,8908,8257,3536,2935,7575,1315,4874,864
  Retained Earnings4.1%9,6459,2618,9118,8059,9679,8989,0479,21010,13813,52515,08111,15910,2459,2688,4297,1236,1575,4714,9175,1854,586
  Additional Paid-In Capital3.0%463449439474463447431472459442421460445429412429424410396411403
Accumulated Depreciation------1,009---1,002---961--876883851850828
Shares Outstanding-2.4%29.0029.0029.0029.0030.0030.0030.0030.0030.0030.0030.0030.0030.0030.0030.0030.0030.0030.0030.0030.0030.00
Float----50.00---10,439---107---86.00---6,613-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-13.9%69,79281,04397,70098,08198,11979,65710,99053,30650,494170,900230,400154,600113,600294,400135,70092,10062,800159,80299,750155,40242,943
  Share Based Compensation-15,300---16,600---------10,800---9,100--
Cashflow From Investing-159.7%-43,09372,197-9,50027,984-70,473-58,552-88,419-144,481-916,141-567,427-81,350-100,277-48,327-59,75390,854-88,573-12,422-61,196-109,909-15,071-22,713
Cashflow From Financing100.0%21.00-200,620-26,598-202,7384,309-86,619-8,772-121,3261,190,2934,635-15,5822,865-47,347-421,884439-2,979-98,617-4,783-4,491-15,6452,161
  Buy Backs-97.6%4,749200,00021,321207,407-90,679-125,000----49,998--1.00-100,0058,0004,99915,001-
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

BIO Income Statement

2024-03-31
Condensed Consolidated Statements of Income (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]  
Net sales$ 610,820$ 676,844
Cost of goods sold284,854314,427
Gross profit325,966362,417
Selling, general and administrative expense214,883225,553
Research and Development Expense66,37574,951
Segment profit (loss)44,70861,913
Interest expense12,27712,337
Foreign exchange (gains) losses, net(1,954)(2,347)
Marketable Securities, Unrealized (Gain) Loss(422,177)17,525
Other Nonoperating Income (Expense)34,51650,431
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest491,07884,829
(Provision) benefit for income taxes(107,162)(15,867)
Net income attributable to Bio-Rad$ 383,916$ 68,962
Basic earnings per share:  
Net income per share basic attributable to Bio-Rad$ 13.46$ 2.33
Weighted average common shares - basic28,51829,596
Diluted earnings per share:  
Net income per share diluted attributable to Bio-Rad$ 13.45$ 2.32
Weighted average common shares - diluted28,53729,747

BIO Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
ASSETS:  
Cash and cash equivalents$ 433,280$ 403,815
Short-term investments1,212,3941,203,327
Restricted investments5,5605,560
Accounts receivable, net444,809489,017
Inventory783,369780,517
Prepaid expenses142,742140,040
Other current assets38,78226,054
Total current assets3,060,9363,048,330
Property, plant and equipment, net522,364529,007
Operating lease right-of-use assets188,918194,730
Goodwill, net412,817413,569
Purchased intangibles, net313,602320,514
Other investments8,018,3837,698,070
Other assets92,87394,850
Assets12,609,89312,299,070
LIABILITIES AND STOCKHOLDERS' EQUITY:  
Accounts payable102,750144,625
Accrued payroll and employee benefits146,491139,929
Current maturities of long-term debt and notes payable487486
Income and other taxes payable33,96135,759
Current operating lease liabilities40,03840,379
Other current liabilities142,427161,621
Total current liabilities466,154522,799
Long-term debt, net of current maturities1,199,3811,199,052
Deferred income taxes1,540,9921,475,495
Operating lease liabilities159,814165,478
Other long-term liabilities192,418195,113
Total liabilities3,558,7593,557,937
Stockholders' equity:  
Additional paid-in capital462,627449,075
Retained earnings9,644,5459,260,629
Accumulated other comprehensive loss(425,971)(336,038)
Total stockholders' equity9,051,1348,741,133
Total liabilities and stockholders' equity12,609,89312,299,070
Common Class A [Member]  
Stockholders' equity:  
Common stock22
Common Class B [Member]  
Stockholders' equity:  
Common stock11
Treasury Stock, Common  
Stockholders' equity:  
Treasury stock$ (630,070)$ (632,536)
BIO
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
 CEO
 WEBSITEbio-rad.com
 INDUSTRYMedical Instruments & Supplies
 EMPLOYEES8200

Bio-Rad Laboratories Inc Frequently Asked Questions


What is the ticker symbol for Bio-Rad Laboratories Inc? What does BIO stand for in stocks?

BIO is the stock ticker symbol of Bio-Rad Laboratories Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Bio-Rad Laboratories Inc (BIO)?

As of Fri Jul 19 2024, market cap of Bio-Rad Laboratories Inc is 8.46 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BIO stock?

You can check BIO's fair value in chart for subscribers.

What is the fair value of BIO stock?

You can check BIO's fair value in chart for subscribers. The fair value of Bio-Rad Laboratories Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Bio-Rad Laboratories Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BIO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Bio-Rad Laboratories Inc a good stock to buy?

The fair value guage provides a quick view whether BIO is over valued or under valued. Whether Bio-Rad Laboratories Inc is cheap or expensive depends on the assumptions which impact Bio-Rad Laboratories Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BIO.

What is Bio-Rad Laboratories Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 19 2024, BIO's PE ratio (Price to Earnings) is -26.25 and Price to Sales (PS) ratio is 3.25. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BIO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Bio-Rad Laboratories Inc's stock?

In the past 10 years, Bio-Rad Laboratories Inc has provided 0.096 (multiply by 100 for percentage) rate of return.